Quantum-Si incorporated operates first next-generation protein sequencing and genomics platform for healthcare industries. It offers a single molecule detection solution to decode the molecules of life, including sample preparation, single molecule, massively parallel, and protein identification. The company's technology has the applications in proteomics, single cell, transcriptomics, genomics, metabolomics, and drug testing and screening fields. The company is based in Guilford, Connecticut. Quantum-Si incorporated is a subsidiary of 4Catalyzer Corporation.
IPO Year: 2020
Exchange: NASDAQ
Website: quantum-si.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2023 | $3.00 | Buy | H.C. Wainwright |
| 9/25/2023 | $3.50 → $2.00 | Buy → Hold | Canaccord Genuity |
| 10/20/2021 | $13.00 | Buy | Canaccord Genuity |
H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00
Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously
Canaccord Genuity initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $13.00
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
3 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
3 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
4 - Quantum-Si Inc (0001816431) (Issuer)
Sales Pipeline is Accelerating and New Kits Remain on Track for Q4 Launch Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024. Press Release Highlights Reported revenue of $787,000 for the third quarter of 2024 Announced that Liberate Bio has integrated Platinum® Next-Generation Sequencing into their platform for developing novel gene therapies with improved targeting capabilities Announced appointments of industry veteran Todd Bennett as Chief Commercial Officer ("CCO"), John Vieceli, Ph.D. as Chief Product Officer and Lindsay Thompson as C
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the third quarter of 2024 on Tuesday, November 12, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:00 AM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event
Announces Release of Version 3 Sequencing Kit Announces Two Additional Kit Launches Expected by End of 2024 Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the second quarter ended June 30, 2024. Press Release Highlights Reported revenue of $622,000 in the second quarter of 2024 Completed the first quarter of full commercial launch of the Platinum® instrument in Q2 2024 Announces the launch of the version 3 sequencing kit Announced appointment of Chuck Kummeth as independent Chairman of the Board of Directors Expect to l
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the second quarter of 2024 on Wednesday, August 7, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the eve
Executed Full Commercial Launch of Platinum® Instrument Reaffirms Full Year 2024 Financial Guidance Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the first quarter ended March 31, 2024. Press Release Highlights Reported revenue of $457,000 in the first quarter of 2024 Commenced its full commercial launch of its Platinum® instrument at the end of March 2024 On track to launch version 3 of its sequencing kit, which is expected by the end of Q3 2024 Announced addition of Paula Dowdy to the Board of Directors Announced the release of a new version of Platinum® Analysis Soft
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will report financial results for the first quarter 2024 on Thursday, May 9, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will b
Finalizing Commercial Readiness for Expected Full Commercial Launch by the End of Q1 2024 Releases Full Year 2024 Financial Guidance Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023. Press Release Highlights Recorded revenue of $400,000 in the fourth quarter of 2023 as the Company continued its previously communicated controlled commercial launch of its Platinum® instrument Finalizing commercial readiness for expected full commercial launch by the end of Q1 2024 Launched version 2 of its sequencing kit in early February 2
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcas
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced financial results for the third quarter ended September 30, 2023. Third Quarter Highlights Recorded revenue of $223,000 in the third quarter of 2023 as the Company continued its previously communicated controlled commercial launch of its Platinum instrument Completed a strategic review of research and development ("R&D") programs and organizational design; resulting changes will focus development on rapid delivery of capabilities and applications with the highest customer demand First customer data presented in an October webinar titled "Next-generation p
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the third quarter 2023 on Thursday, November 9, 2023. Company management will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events & Presentations. Alternatively, individuals can register online to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event wi
SC 13D/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G - Quantum-Si Inc (0001816431) (Subject)
SC 13G - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13D/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G/A - Quantum-Si Inc (0001816431) (Subject)
SC 13G - Quantum-Si Inc (0001816431) (Subject)
SCHEDULE 13G/A - Quantum-Si Inc (0001816431) (Subject)
8-K - Quantum-Si Inc (0001816431) (Filer)
424B5 - Quantum-Si Inc (0001816431) (Filer)
SCHEDULE 13D/A - Quantum-Si Inc (0001816431) (Subject)
144 - Quantum-Si Inc (0001816431) (Subject)
8-K - Quantum-Si Inc (0001816431) (Filer)
424B5 - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
8-K - Quantum-Si Inc (0001816431) (Filer)
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 44,893 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces the launch of Platinum® Pro, its latest benchtop sequencer that sets a new standard in protein analysis. Designed to redefine efficiency and versatility in proteomics research, Platinum Pro is now available for ordering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113845303/en/The new Platinum® Pro system from Quantum-Si is now available to order. (Photo: Business Wire) Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins in a simple, integrated workflow. Its design priorit
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces the release of its latest preprint titled "Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis, and Tracking." This study highlights the potential of integrating Quantum-Si's benchtop Platinum® instrument with an innovative protein barcoding workflow, offering a sensitive and accessible approach to multiplexed protein analysis. Protein barcoding has emerged as a powerful tool for multiplexed protein selection, analysis, and tracking, enabling advanced insights into proteomics research. Traditional detection methods, such a
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 15,625,000 shares of common stock at a purchase price of $3.20 per share, pursuant to a registered direct offering, resulting in gross proceeds of approximately $50 million, before deducting placement agent commissions and other offering expenses. The closing of the offering is expected to occur on or about January 6, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering
Announces early access availability of ProteoVue Software ProteoVue is part of broader set of innovation initiatives, including the Company's recently announced collaboration with NVIDIA, to leverage AI to enhance sequencing performance Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced a new paper that was submitted to BioRxiv, demonstrating the capabilities of its proprietary bioinformatics tool called ProteoVue, for detecting and quantifying Single Amino Acid Variants (SAAVs). The paper, titled "Detecting Amino Acid Variants Using Next-Generation Protein Sequencing (NGPS)," highlights the transformative potent
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si's Board of Directors has granted 46,666 restricted stock units ("RSUs") to new employees under the Company's previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the "2023 Inducement Plan"). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4). The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si
Expands Distribution Network to Accelerate Global Adoption of Platinum® Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announced that it has expanded its international distribution network to a total of 15 partners. The commercial distribution network includes further expansion across Western Europe, Eastern Europe and Asia, as well as new expansion into Middle East, Africa, South America and the South Pacific regions. "We have made significant progress in expanding our international distribution network over the last several months, assembling an outstanding network of partners that are well positioned to drive adoption o
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, has introduced the Platinum Library Prep Kit, V2, an advanced tool for single-molecule protein sequencing that is designed to simplify workflows and expand researchers' ability to analyze the proteome. The new kit is designed to deliver significant advancements in accessibility and efficiency, offering researchers a streamlined library preparation process that reduces hands-on time to under two hours while maintaining precision and reliability. Key features include: Improved Performance: 85% of proteins attempted generated successful libraries and sequencing results, expandin
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, has announced the launch of its protein Barcoding Kit designed to transform protein research by empowering researchers with an advanced multiplexed protein screening solution. The protein Barcoding Kit offers a multiplexed solution for efficient protein screening using peptide barcodes, tailored to the needs of biopharma research. It supports critical applications such as optimizing lipid nanoparticle (LNP), evaluating mRNA therapeutics, and analyzing protein characteristics. The kit reduces time and costs through streamlined workflows while delivering relative quantitation acro
Provides Update on the Company's Innovation Roadmap & New Development Partnerships Highlights new Distribution Agreement with Avantor in the U.S. and Canada Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the highlights of an Investor & Analyst event that was hosted in New York City on November 20th, 2024. Quantum-Si's Management team announced Platinum™ Pro, the Company's evolution of Platinum, as well as Proteus™, the Company's new cutting-edge proteomics platform of the future, that is now under development. "We are very excited to have this opportunity to unveil the rapid innovation that we have achiev
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new international distributor as demand grows for its first-to-market next-generation protein sequencing™ instrument, Platinum™. 3Genes Distribution a.s., a prominent technology provider specializing in life science and diagnostics in Eastern Europe will distribute Quantum-Si's Platinum across the Czech Republic, Slovakia, and Hungary. Dominik Véle, a board member of 3Genes said, "Through our agreement with Quantum-Si, 3Genes aims to pioneer proteomic innovation in our Eastern European markets, forging a new era in life
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it had entered into an agreement with Elta 90 to distribute Quantum-Si's groundbreaking Platinum™ instrument and consumables in Southeast Europe as demand grows for the first of its kind next-generation protein sequencing™ platform. This agreement between Quantum-Si and ELTA 90 holds immense promise for accelerating scientific research by delivering the game changing tool, Platinum, which interrogates proteins with single-molecule amino acid resolution. "We are thrilled to partner with ELTA 90 in this venture. The synergy between Quantum-Si and ELTA 90 repre
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced it has received the "Proteomics Company of the Year" award from the BioTech Breakthrough Awards as part of the program's 2023 award recipients for its first of a kind protein sequencing instrument. "Since the groundbreaking introduction of Platinum™, Quantum-Si has swiftly emerged as an industry trailblazer, galvanizing the scientific community with a pioneering focus on proteomics," said Quantum-Si Chief Executive Officer Jeff Hawkins. "Receiving the coveted Proteomics Company of the Year award in 2023 is a testament to the extraordinary caliber of our team and th
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced it will showcase next-generation benchtop protein sequencing instrument, Platinum™, and the Company's vision to transform genomics and proteomics research, at the American Society of Human Genetics (ASHG) conference, in Washington, D.C., November 1-5. "Platinum, stands as a groundbreaking advancement in next-generation protein sequencing™ moving the field beyond the limitations posed by mass spectrometry and immunoassays. This robust tool is a solution, enabling precise, single-molecule resolution," remarked Quantum-Si Chief Executive Officer Jeff Hawkins. He conti
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Amir Jafri, President and CEO of Immunicom, Inc., to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230921747791/en/(Photo: Business Wire) "Amir's leadership track record speaks for itself," said Jeff Hawkins, CEO of Quantum-Si. "He has successfully managed businesses across multiple industries and has built and led world class R&D organizations responsible for advanced technology development and the launch of over 50 products and technologies globally. His exper
Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Johan Denecke as Senior Vice President of Operations, effective June 20, 2023. Mr. Denecke will be responsible for scaling up production and driving operational and quality excellence in support of the commercialization of Quantum-Si's next-generation, single-molecule protein sequencing platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230621345723/en/(Photo: Business Wire) Mr. Denecke brings more than 20 years of experience as a cross-functional operations executive in engineeri
World-class laboratory and office space underpins the scaling of Quantum-Si's operational and development capabilities in support of its goal to revolutionize protein sequencing. Company continues rich 10 year history in Connecticut with new facility through 2029 Quantum-Si- Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the official debut of The Company's new state-of-the-art, 29,420 square-foot headquarters in Branford, Connecticut. The new facility extends The Company's decade long history in Connecticut, and includes a 7-year lease which will keep Quantum-Si in Branford at least through 2029. The official ribbon cut